

Concepcion Palomo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9162657/publications.pdf>

Version: 2024-02-01

29
papers

1,405
citations

430442

18
h-index

476904

29
g-index

29
all docs

29
docs citations

29
times ranked

1816
citing authors

#	ARTICLE	IF	CITATIONS
1	Major changes in the G protein of human respiratory syncytial virus isolates introduced by a duplication of 60 nucleotides. <i>Journal of General Virology</i> , 2003, 84, 3115-3120.	1.3	226
2	Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6-13.	1.4	222
3	Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3089-3094.	3.3	217
4	Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein. <i>PLoS Pathogens</i> , 2015, 11, e1005035.	2.1	106
5	Effect of Proteolytic Processing at Two Distinct Sites on Shape and Aggregation of an Anchorless Fusion Protein of Human Respiratory Syncytial Virus and Fate of the Intervening Segment. <i>Virology</i> , 2002, 298, 317-326.	1.1	66
6	Evaluation of the antibody specificities of human convalescent-phase sera against the attachment (G) protein of human respiratory syncytial virus: Influence of strain variation and carbohydrate side chains. <i>Journal of Medical Virology</i> , 2000, 60, 468-474.	2.5	65
7	Neutralization of Human Respiratory Syncytial Virus Infectivity by Antibodies and Low-Molecular-Weight Compounds Targeted against the Fusion Glycoprotein. <i>Journal of Virology</i> , 2010, 84, 7970-7982.	1.5	54
8	Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation. <i>PLoS Pathogens</i> , 2016, 12, e1005859.	2.1	50
9	Characterization of the epitope for anti-human respiratory syncytial virus F protein monoclonal antibody 101F using synthetic peptides and genetic approaches. <i>Journal of General Virology</i> , 2007, 88, 2719-2723.	1.3	48
10	Genetic and Antigenic Variability of Human Respiratory Syncytial Virus (Groups A and B) Isolated over Seven Consecutive Seasons in Argentina (1995 to 2001). <i>Journal of Clinical Microbiology</i> , 2005, 43, 2266-2273.	1.8	45
11	A Monomeric Uncleaved Respiratory Syncytial Virus F Antigen Retains Prefusion-Specific Neutralizing Epitopes. <i>Journal of Virology</i> , 2014, 88, 11802-11810.	1.5	38
12	The Three C-Terminal Residues of Human Respiratory Syncytial Virus G Glycoprotein (Long Strain) Are Essential for Integrity of Multiple Epitopes Distinguishable by Antiidiotypic Antibodies. <i>Viral Immunology</i> , 1995, 8, 37-46.	0.6	31
13	Trivalency of a Nanobody Specific for the Human Respiratory Syncytial Virus Fusion Glycoprotein Drastically Enhances Virus Neutralization and Impacts Escape Mutant Selection. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6498-6509.	1.4	30
14	Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses. <i>Journal of Virology</i> , 2016, 90, 5485-5498.	1.5	29
15	Studies on the activation of the heme-stabilized translational inhibitor of reticulocyte lysates by oxidized glutathione and NADPH depletion. <i>Archives of Biochemistry and Biophysics</i> , 1985, 239, 497-507.	1.4	27
16	Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins. <i>Nature Communications</i> , 2022, 13, 1299.	5.8	26
17	Comparison of affinity chromatography and adsorption to vaccinia virus recombinant infected cells for depletion of antibodies directed against respiratory syncytial virus glycoproteins present in a human immunoglobulin preparation. <i>Journal of Medical Virology</i> , 2005, 76, 248-255.	2.5	25
18	Intragroup antigenic diversity of human respiratory syncytial virus (group A) isolated in Argentina and Chile. <i>Journal of Medical Virology</i> , 2005, 77, 311-316.	2.5	20

#	ARTICLE	IF	CITATIONS
19	Recombinant Soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and Is Not Cleaved Displays Prefusion-Like Characteristics. <i>PLoS ONE</i> , 2015, 10, e0130829.	1.1	15
20	The Complexity of Antibody Responses Elicited against the Respiratory Syncytial Virus Glycoproteins in Hospitalized Children Younger than 2 Years. <i>Frontiers in Microbiology</i> , 2017, 8, 2301.	1.5	13
21	Polyclonal and monoclonal antibodies specific for the six-helix bundle of the human respiratory syncytial virus fusion glycoprotein as probes of the protein post-fusion conformation. <i>Virology</i> , 2014, 460-461, 119-127.	1.1	11
22	Comparison of antibodies directed against human respiratory syncytial virus antigens present in two commercial preparations of human immunoglobulins with different neutralizing activities. <i>Vaccine</i> , 2004, 23, 435-443.	1.7	10
23	Proteomics Analysis Reveals That Structural Proteins of the Virion Core and Involved in Gene Expression Are the Main Source for HLA Class II Ligands in Vaccinia Virus-Infected Cells. <i>Journal of Proteome Research</i> , 2019, 18, 900-911.	1.8	8
24	Generation of monoclonal antibodies specific of the postfusion conformation of the Pneumovirinae fusion (F) protein. <i>Journal of Virological Methods</i> , 2015, 224, 1-8.	1.0	7
25	Natural Spleen Cell Ligandome in Transporter Antigen Processing-Deficient Mice. <i>Journal of Proteome Research</i> , 2019, 18, 3512-3520.	1.8	7
26	Immunoproteomic analysis of a Chikungunya poxvirus-based vaccine reveals high HLA class II immunoprevalence. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007547.	1.3	4
27	Note on the activation of the heme-stabilized translational inhibitor of reticulocyte lysates by oxidized glutathione. <i>Biochimie</i> , 1988, 70, 827-831.	1.3	2
28	Prevalence of anti-human respiratory syncytial virus antibodies over three consecutive years in a healthy adult population. <i>Journal of Medical Virology</i> , 2003, 71, 298-304.	2.5	2
29	Evaluation of the antibody specificities of human convalescent-phase sera against the attachment (G) protein of human respiratory syncytial virus: Influence of strain variation and carbohydrate side chains. <i>Journal of Medical Virology</i> , 2000, 60, 468.	2.5	1